2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P04. Non-Small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model

P04. Non-Small Cell Lung Cancer (NSCLC) Comprehensive Genomic Profiling: Integrating Expanded Genomic Sequencing Into the Canadian Publicly Funded Health Care Model - PDF

Back to course

Pdf Summary

A study conducted at Princess Margaret Cancer Centre in Toronto, Canada, evaluated the integration of comprehensive genomic profiling (CGP) into the publicly funded healthcare system for non-small cell lung cancer (NSCLC) patients. The current standard of care molecular testing for NSCLC patients in Ontario includes testing for specific gene alterations. However, this study aimed to determine the potential benefits and costs of implementing CGP, which allows for broader targeted treatment options by identifying additional actionable targets.<br /><br />The study included 182 stage IV NSCLC patients who did not have the known gene alterations being tested for in the standard of care. The patients' tumor specimens were tested using CGP, and the primary endpoints were the identification of incremental actionable targets and clinical trial opportunities resulting from CGP. Secondary endpoints included treatment outcomes and costs from the perspective of the Canadian public healthcare system.<br /><br />Out of the enrolled patients, 74% completed CGP, and actionable targets beyond the standard of care testing were identified in 28% of patients. These targets included alterations in genes such as ERBB2, BRAF, RET, NRG, MET, KRAS, EGFR, and ROS-1. Additionally, new clinical trial options were identified for 75% of patients. As a result of CGP, 16% of patients had a change to their anti-cancer therapy, all of whom received targeted therapy.<br /><br />The main barrier to implementing CGP in the publicly funded healthcare system was the lack of funding. The study estimated incremental costs of CGP per case ranging from 270-710 CAD, depending on whether costs were based on a research or clinical laboratory setting. However, it is expected that the cost of CGP will decrease over time as more Health Canada-approved treatments targeting novel biomarkers become available.<br /><br />Overall, the study concluded that CGP can consolidate genomic testing, identify additional actionable targets, increase clinical trial eligibility, and directly impact anti-cancer treatment for NSCLC patients. However, the lack of funding for CGP in the Canadian publicly funded health system presents a challenge for implementation.

Asset Subtitle

Kirstin Perdrizet

Meta Tag

Speaker Kirstin Perdrizet

Topic Immunotherapy - Other Immunologic

Keywords

comprehensive genomic profiling

non-small cell lung cancer

NSCLC

gene alterations

targeted treatment options

actionable targets

clinical trial opportunities

treatment outcomes

costs

publicly funded healthcare system